PE20121025A1 - Compuestos de benzoxazepina como inhibidores de la p13k - Google Patents
Compuestos de benzoxazepina como inhibidores de la p13kInfo
- Publication number
- PE20121025A1 PE20121025A1 PE2012000390A PE2012000390A PE20121025A1 PE 20121025 A1 PE20121025 A1 PE 20121025A1 PE 2012000390 A PE2012000390 A PE 2012000390A PE 2012000390 A PE2012000390 A PE 2012000390A PE 20121025 A1 PE20121025 A1 PE 20121025A1
- Authority
- PE
- Peru
- Prior art keywords
- benzoxazepine
- oxazepine
- nr5r6
- triazol
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
REFERIDA A UN DERIVADO DE BENZOXAZEPINA DE FORMULA (I), DONDE Z1 ES CR1 O N; Z2 ES CR2 O N; Z3 ES CR3 O N; Z4 ES CR4 O N; B ES UN ANILLO PIRAZOLILO O IMIDAZOLILO FUSIONADO CON EL ANILLO DE LA BENZOXAZEPINA TAL COMO (a), (b), (c), ENTRE OTROS; R1, R2, R3 Y R4 SON H, F, CN, NO2, ENTRE OTROS; A ES C(=O)NR5R6, NR5R6, ENTRE OTROS; R5 ES H O ALQUILO C1-C12 OPCIONALMENTE SUSTITUIDO CON F, Cl, CN, COOH, ENTRE OTROS; R6 ES ALQUILO C1-C12, ARILO C6-C20, CARBOCICLILO C3-C12, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(2,4-DIFLUORFENIL)-N-METIL-4,5-DIHIDROBENZO[b]PIRAZOLO-[1,5-d][1,4]OXAZEPINA-2-CARBOXAMIDA, 2-(1-(2-CLOROFENIL)-1H-1,2,4-TRIAZOL-5-IL)-5,6-DIHIDRO-BENZO[f]IMIDAZO[1,2-d][1,4]-OXAZEPINA-10-CARBOXAMIDA, 2-(1-(2,4-DIFLUORFENIL)-1H-1,2,4-TRIAZOL-5-IL)-8-BROMO-4,5-DIHIDROBENZO-2H-OXEPINO-[4,5-d]PIRAZOL, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE LA QUINASA PI3 Y SON UTILES EN EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24638109P | 2009-09-28 | 2009-09-28 | |
| US33068510P | 2010-05-03 | 2010-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121025A1 true PE20121025A1 (es) | 2012-08-06 |
Family
ID=43037239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000390A PE20121025A1 (es) | 2009-09-28 | 2010-09-27 | Compuestos de benzoxazepina como inhibidores de la p13k |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US8242104B2 (es) |
| EP (3) | EP2711368B1 (es) |
| JP (2) | JP5540101B2 (es) |
| KR (1) | KR101428346B1 (es) |
| CN (2) | CN102762576B (es) |
| AR (1) | AR078187A1 (es) |
| AU (1) | AU2010299816C1 (es) |
| BR (1) | BR112012006807A2 (es) |
| CA (1) | CA2772691C (es) |
| CL (1) | CL2012000754A1 (es) |
| CO (1) | CO6491026A2 (es) |
| CR (1) | CR20120121A (es) |
| DK (1) | DK2483278T3 (es) |
| EC (1) | ECSP12011755A (es) |
| ES (2) | ES2444779T3 (es) |
| HR (1) | HRP20140229T1 (es) |
| IL (2) | IL217558A (es) |
| MA (1) | MA33531B1 (es) |
| MX (1) | MX2012003591A (es) |
| MY (2) | MY184074A (es) |
| NZ (1) | NZ597833A (es) |
| PE (1) | PE20121025A1 (es) |
| PL (1) | PL2483278T3 (es) |
| PT (1) | PT2483278E (es) |
| RS (1) | RS53164B (es) |
| RU (2) | RU2600927C2 (es) |
| SG (1) | SG10201405049RA (es) |
| SI (1) | SI2483278T1 (es) |
| TW (1) | TWI423980B (es) |
| WO (1) | WO2011036280A1 (es) |
| ZA (1) | ZA201202199B (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598942A (en) * | 2009-07-27 | 2014-02-28 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| BR112012006802A2 (pt) * | 2009-09-28 | 2020-08-18 | F.Hoffmann-La Roche Ag | composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção |
| AR078187A1 (es) * | 2009-09-28 | 2011-10-19 | Hoffmann La Roche | Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer. |
| ES2529119T3 (es) | 2010-07-02 | 2015-02-17 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
| US9090628B2 (en) | 2011-03-21 | 2015-07-28 | Genentech, Inc. | Benzoxazepin compounds selective for PI3K P110 delta and methods of use |
| ES2785475T3 (es) | 2011-05-10 | 2020-10-07 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores de canales iónicos |
| WO2012156379A1 (en) | 2011-05-13 | 2012-11-22 | Universität Zürich | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| NO3175985T3 (es) * | 2011-07-01 | 2018-04-28 | ||
| CN104284899A (zh) | 2012-02-17 | 2015-01-14 | 弗·哈夫曼-拉罗切有限公司 | 三环化合物和其应用方法 |
| KR101689946B1 (ko) * | 2012-06-08 | 2016-12-26 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
| BR112014032346A2 (pt) | 2012-06-26 | 2017-06-27 | Del Mar Pharmaceuticals | métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes |
| CN102775395A (zh) * | 2012-07-12 | 2012-11-14 | 江苏七洲绿色化工股份有限公司 | 一种丙环唑的制备方法及丙环唑中间体 |
| US9303046B2 (en) * | 2012-08-07 | 2016-04-05 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
| AR095365A1 (es) * | 2013-03-13 | 2015-10-14 | Hoffmann La Roche | Procedimiento para preparar compuestos benzoxazepina |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| KR20180093138A (ko) * | 2013-12-16 | 2018-08-20 | 에프. 호프만-라 로슈 아게 | 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도 |
| US20150258080A1 (en) | 2014-03-13 | 2015-09-17 | Genentech, Inc. | Therapeutic combinations with estrogen receptor modulators |
| JP6668362B2 (ja) | 2015-02-02 | 2020-03-18 | フォーマ セラピューティクス，インコーポレイテッド | Ｈｄａｃ阻害薬としての３−アルキル−４−アミド−二環式［４，５，０］ヒドロキサム酸 |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
| WO2016174616A1 (en) * | 2015-04-30 | 2016-11-03 | Novartis Ag | Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors |
| AU2016278040B2 (en) | 2015-06-16 | 2019-07-04 | Nanophagix LLC | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| CN107635560A (zh) | 2015-06-29 | 2018-01-26 | 豪夫迈·罗氏有限公司 | 用他塞利昔布进行治疗的方法 |
| EP3317283B1 (en) * | 2015-07-02 | 2019-04-03 | H. Hoffnabb-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| KR102306071B1 (ko) * | 2015-07-02 | 2021-10-01 | 에프. 호프만-라 로슈 아게 | 벤즈옥사제핀 옥사졸리디논 화합물 및 사용 방법 |
| EP3347361B1 (en) | 2015-09-08 | 2020-08-05 | H. Hoffnabb-La Roche Ag | Tricyclic pi3k inhibitor compounds and methods of use |
| US9721369B2 (en) * | 2015-09-15 | 2017-08-01 | Facebook, Inc. | Systems and methods for utilizing multiple map portions from multiple map data sources |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| CR20190165A (es) | 2016-09-29 | 2019-07-09 | Bayer Ag | Novedosos derivados de imidazolilmetilo 5-sustituidos |
| SG10201913961PA (en) | 2016-12-15 | 2020-03-30 | Hoffmann La Roche | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide |
| MX388169B (es) | 2017-03-02 | 2025-03-19 | Genentech Inc | Pertuzumab para usarse en el tratamiento de cáncer de mama her2 positivo. |
| CN110650963B (zh) | 2017-04-28 | 2022-09-27 | 豪夫迈·罗氏有限公司 | Gdc-0077的多晶型物和固体形式及其制备方法 |
| US11306086B2 (en) * | 2017-10-26 | 2022-04-19 | Xynomic Pharmaceuticals, Inc. | Crystalline salts of a B-RAF kinase inhibitor |
| CN114835729B (zh) * | 2018-05-30 | 2024-05-31 | 江苏豪森药业集团有限公司 | 含三并环类衍生物抑制剂、其制备方法和应用 |
| CN111909157B (zh) * | 2019-05-07 | 2023-02-03 | 南京药石科技股份有限公司 | Ezh2抑制剂及其用途 |
| CN114599656A (zh) * | 2019-11-04 | 2022-06-07 | 贝达药业股份有限公司 | 咪唑烷酮类化合物及其制备方法与应用 |
| MX2022005415A (es) * | 2019-11-04 | 2022-05-26 | Betta Pharmaceuticals Co Ltd | Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo. |
| JP7678808B2 (ja) * | 2019-11-25 | 2025-05-16 | 上▲海▼翰森生物医▲薬▼科技有限公司 | ３種類の縮合環誘導体含有塩又は結晶形態及びその医薬組成物 |
| WO2022233263A1 (zh) * | 2021-05-03 | 2022-11-10 | 山东轩竹医药科技有限公司 | 三并环类泛素特异性蛋白酶1抑制剂及其用途 |
| AU2022275275A1 (en) * | 2021-05-13 | 2023-12-14 | Betta Pharmaceuticals Co., Ltd | Polymorph of imidazolidinone compound, preparation method therefor and use thereof |
| WO2022251567A1 (en) | 2021-05-28 | 2022-12-01 | Genentech, Inc. | Process for the preparation of benzoxazepin oxazolidinone compounds |
| WO2024104435A1 (zh) * | 2022-11-17 | 2024-05-23 | 微境生物医药科技(上海)有限公司 | 三并环类PI3Kα抑制剂及其制备方法和医药用途 |
| CN116003280B (zh) * | 2022-12-30 | 2024-11-19 | 合肥工业大学 | 一种芳基甲酰胺类化合物的光化学合成方法 |
| WO2025082533A1 (zh) * | 2023-10-21 | 2025-04-24 | 上海轶诺药业有限公司 | 一种稠环化合物及其制备和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| GB8504702D0 (en) * | 1985-02-23 | 1985-03-27 | Zyma Sa | Tricyclic compounds |
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| FR2677356B1 (fr) * | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| ATE151418T1 (de) * | 1992-12-28 | 1997-04-15 | Eisai Co Ltd | Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können |
| AU678503B2 (en) * | 1993-09-24 | 1997-05-29 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds and their use as squalene synthetase inhibitors |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| US5985799A (en) * | 1995-11-17 | 1999-11-16 | E.I. Du Pont De Nemours And Company | Tricyclic herbicidal heterocycles |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| DE19908533A1 (de) * | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
| DE19908535A1 (de) * | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| DE19908538A1 (de) * | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
| DE19908537A1 (de) * | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| US7273880B2 (en) * | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
| AU2001246494A1 (en) | 2000-03-03 | 2001-09-12 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
| SK9782003A3 (en) | 2001-02-02 | 2004-01-08 | Schering Corp | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists |
| TWI232863B (en) * | 2001-06-11 | 2005-05-21 | Akzo Nobel Nv | Benzoxazepine derivatives |
| JP2005536518A (ja) * | 2002-07-19 | 2005-12-02 | ファルマシア コーポレイション | 炎症治療のための置換チオフェンカルボキサミド化合物 |
| BRPI0407335A (pt) * | 2003-02-07 | 2006-01-10 | Warner Lambert Co | Agentes antibacterianos |
| TW200510356A (en) * | 2003-08-01 | 2005-03-16 | Takeda Chemical Industries Ltd | Benzoxaepine compounds |
| US20050239767A1 (en) * | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| RU2007103816A (ru) * | 2004-07-01 | 2008-08-10 | Мерк энд Ко., Инк. (US) | Ингибиторы митотического кинезина |
| EP2343303A1 (de) * | 2004-10-07 | 2011-07-13 | Boehringer Ingelheim International GmbH | PI3-Kinase Inhibitoren |
| CA2622755C (en) | 2005-10-07 | 2017-01-31 | Exelixis, Inc. | Azetidines as mek inhibitors |
| US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| US20070238718A1 (en) * | 2006-04-06 | 2007-10-11 | Matthias Grauert | Thiazolyl-dihydro-indazole |
| GB0610866D0 (en) * | 2006-06-02 | 2006-07-12 | Hammersmith Imanet Ltd | Novel in vivo imaging compounds |
| WO2008014483A1 (en) * | 2006-07-28 | 2008-01-31 | Alcan Packaging Flexible France | Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva) |
| EP2054058B1 (en) | 2006-08-04 | 2016-11-09 | Beth Israel Deaconess Medical Center | Inhibitors of pyruvate kinase and methods of treating disease |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| UA100501C2 (uk) * | 2006-12-29 | 2013-01-10 | Ебботт Гмбх Унд Ко. Кг | Карбоксамідні сполуки і їх застосування як інгібіторів кальпаїнів |
| CA2699967C (en) | 2007-09-19 | 2016-11-22 | The Regents Of The University Of California | Positron emission tomography probes for imaging immune activation and selected cancers |
| BRPI0910346A2 (pt) * | 2008-03-31 | 2015-10-06 | Hoffmann La Roche | compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso |
| JP5579724B2 (ja) * | 2008-10-17 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環 |
| AR078187A1 (es) * | 2009-09-28 | 2011-10-19 | Hoffmann La Roche | Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer. |
| BR112012006802A2 (pt) * | 2009-09-28 | 2020-08-18 | F.Hoffmann-La Roche Ag | composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção |
-
2010
- 2010-09-27 AR ARP100103491A patent/AR078187A1/es unknown
- 2010-09-27 RU RU2012117398/04A patent/RU2600927C2/ru active
- 2010-09-27 US US12/890,812 patent/US8242104B2/en active Active
- 2010-09-27 CA CA2772691A patent/CA2772691C/en active Active
- 2010-09-27 MY MYPI2015002473A patent/MY184074A/en unknown
- 2010-09-27 PL PL10757213T patent/PL2483278T3/pl unknown
- 2010-09-27 PT PT107572133T patent/PT2483278E/pt unknown
- 2010-09-27 CN CN201080053938.XA patent/CN102762576B/zh active Active
- 2010-09-27 EP EP13193562.9A patent/EP2711368B1/en active Active
- 2010-09-27 CN CN201510043641.XA patent/CN104744491B/zh active Active
- 2010-09-27 ES ES10757213.3T patent/ES2444779T3/es active Active
- 2010-09-27 BR BR112012006807-5A patent/BR112012006807A2/pt not_active Application Discontinuation
- 2010-09-27 AU AU2010299816A patent/AU2010299816C1/en active Active
- 2010-09-27 DK DK10757213.3T patent/DK2483278T3/da active
- 2010-09-27 HR HRP20140229AT patent/HRP20140229T1/hr unknown
- 2010-09-27 SI SI201030536T patent/SI2483278T1/sl unknown
- 2010-09-27 WO PCT/EP2010/064208 patent/WO2011036280A1/en not_active Ceased
- 2010-09-27 RU RU2016105810A patent/RU2654068C1/ru active
- 2010-09-27 NZ NZ597833A patent/NZ597833A/en unknown
- 2010-09-27 EP EP20140190276 patent/EP2845592A1/en not_active Withdrawn
- 2010-09-27 ES ES13193562T patent/ES2570569T3/es active Active
- 2010-09-27 TW TW099132661A patent/TWI423980B/zh active
- 2010-09-27 MY MYPI2012000823A patent/MY160064A/en unknown
- 2010-09-27 RS RS20140060A patent/RS53164B/sr unknown
- 2010-09-27 JP JP2012530282A patent/JP5540101B2/ja active Active
- 2010-09-27 EP EP10757213.3A patent/EP2483278B1/en active Active
- 2010-09-27 PE PE2012000390A patent/PE20121025A1/es active IP Right Grant
- 2010-09-27 SG SG10201405049RA patent/SG10201405049RA/en unknown
- 2010-09-27 KR KR1020127010974A patent/KR101428346B1/ko active Active
- 2010-09-27 MX MX2012003591A patent/MX2012003591A/es active IP Right Grant
-
2012
- 2012-01-10 CO CO12002995A patent/CO6491026A2/es active IP Right Grant
- 2012-01-16 IL IL217558A patent/IL217558A/en active IP Right Grant
- 2012-02-15 MA MA34637A patent/MA33531B1/fr unknown
- 2012-03-13 CR CR20120121A patent/CR20120121A/es unknown
- 2012-03-26 ZA ZA2012/02199A patent/ZA201202199B/en unknown
- 2012-03-27 CL CL2012000754A patent/CL2012000754A1/es unknown
- 2012-03-28 EC ECSP12011755 patent/ECSP12011755A/es unknown
- 2012-05-22 US US13/477,587 patent/US8343955B2/en active Active
- 2012-11-20 US US13/681,763 patent/US8586574B2/en active Active
-
2013
- 2013-10-07 US US14/047,206 patent/US8785626B2/en active Active
- 2013-11-01 JP JP2013228826A patent/JP5625101B2/ja active Active
-
2014
- 2014-06-05 US US14/297,142 patent/US9198918B2/en active Active
-
2015
- 2015-05-28 IL IL239081A patent/IL239081B/en active IP Right Grant
- 2015-11-03 US US14/930,929 patent/US9546178B2/en active Active
-
2016
- 2016-12-05 US US15/368,937 patent/US9670228B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121025A1 (es) | Compuestos de benzoxazepina como inhibidores de la p13k | |
| PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
| PE20141655A1 (es) | Compuestos de imidazopirrolidinona | |
| PE20120107A1 (es) | Inhibidores de proteina cinasa | |
| PE20120121A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| PE20121559A1 (es) | Compuestos de benzoxepina inhibidores de la p13k | |
| PE20080315A1 (es) | DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3 | |
| PE20120629A1 (es) | Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina | |
| AR112833A2 (es) | Compuestos pirazolo[1,5-a]pirimidina sustituida como inhibidores de trk cinasa | |
| AR119210A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| PE20121150A1 (es) | Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer | |
| CR20120389A (es) | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE cFMS | |
| PE20110828A1 (es) | Compuestos de pirazolopirimidina como inhibidores de jak | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20090596A1 (es) | Imidazoles biciclicos fusionados | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20120493A1 (es) | Pirimidinonas como inhibidores de pi3k | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| NZ599932A (en) | Imidazopyridine derivatives as jak inhibitors | |
| PE20090492A1 (es) | Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3 | |
| PH12014502224A1 (en) | Heterobicyclic compounds as beta-lactamase inhibitors | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| PE20130346A1 (es) | Compuestos heterociclicos fusionados | |
| EA201400338A1 (ru) | Производные аминопиримидина для применения в качестве модуляторов киназной активности | |
| UA104731C2 (ru) | Ингибиторы р38 мар-киназ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |